Monday, July 06, 2015 9:40:33 AM
Enzon Pharmaceuticals, Inc. (Enzon) is a biotechnology company. The Company is dedicated to the research and development of innovative therapeutics for patients with high unmet medical needs. The Company receives royalty revenues on seven marketed products that utilize its Customized PEGylation Linker Technology (Customized Linker Technology) platform, namely PegIntron, Sylatron, Macugen, CIMZIA, OMONTYS, Oncaspar and Adagen. PEGINTRON is a PEG-enhanced version of Merck’s alpha interferon product, INTRON A, which is used both as a monotherapy and in combination with REBETOL (ribavirin) capsules for the treatment of chronic hepatitis C. Sylatron is approved for the adjuvant treatment of melanoma. Macugen (pegaptanib sodium injection) is being marketed by Valeant and Pfizer for the treatment of neovascular (wet) age-related macular degeneration, an eye disease associated with aging that destroys central vision.
DUKE BASKETBALL and NOTRE DAME FOOTBALL
Recent ENZN News
- Form 8-A12G - Registration of securities [Section 12(g)] • Edgar (US Regulatory) • 05/05/2026 08:13:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 08:10:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/04/2026 08:16:10 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 12:56:12 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/29/2026 08:57:54 PM
- Enzon Announces Completion of the Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock • GlobeNewswire Inc. • 03/25/2026 12:45:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 03/25/2026 12:38:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 12:36:13 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 03/25/2026 12:33:16 PM
- Enzon Announces Reverse Stock Split • GlobeNewswire Inc. • 03/24/2026 12:45:00 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 03/24/2026 12:35:53 PM
- Form 8-A12G/A - Registration of securities [Section 12(g)]: [Amend] • Edgar (US Regulatory) • 03/24/2026 12:33:09 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 03/24/2026 12:30:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 12:30:15 PM
- Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock • GlobeNewswire Inc. • 03/19/2026 08:30:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 03/19/2026 08:18:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 08:16:32 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 03/19/2026 08:07:03 PM
- Form 8-A12G/A - Registration of securities [Section 12(g)]: [Amend] • Edgar (US Regulatory) • 03/18/2026 12:52:08 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 03/18/2026 12:48:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/18/2026 12:45:26 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 03/16/2026 08:10:19 PM
- Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock • GlobeNewswire Inc. • 03/16/2026 08:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 08:05:43 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 03/16/2026 08:00:54 PM
